Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer.
cyclin-dependent kinase inhibitors
cyclin-dependent kinases
endometrial cancer
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
12 May 2019
12 May 2019
Historique:
received:
28
02
2019
revised:
15
04
2019
accepted:
10
05
2019
entrez:
15
5
2019
pubmed:
15
5
2019
medline:
20
8
2019
Statut:
epublish
Résumé
Endometrial Cancer (EC) is an important cause of death in women worldwide. Despite early diagnosis and optimal treatment of localized disease, relapsed patients have few therapeutic options because after first line therapy, currently no standard of care exists. On the basis of endocrine positivity of most endometrioid ECs, Endocrine Therapy (ET) is a reasonable and widely accepted option. Better knowledge of molecular mechanisms involved in cancer highlighted the deregulated activity of Cyclin-Dependent Kinases (CDKs) in the cell cycle as a hallmark of carcinogenesis supporting the development of a new class of drugs: CDK inhibitors (CDKis). The aim of this review is to give an overview on CDKis preclinical, early clinical activity and future development in EC. Use of CDKis has a strong preclinical rationale but we have poor clinical data. Similar to breast cancer, most ongoing trials are investigating synergistic associations between CDKis and ET. These trials will probably help in defining the best clinical setting of CDKis in ECs, which are the best partner drugs, and how to manage CDKis toxicities with a focus on potential biomarkers of response.
Identifiants
pubmed: 31083638
pii: ijms20092353
doi: 10.3390/ijms20092353
pmc: PMC6539322
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
Cyclin-Dependent Kinases
EC 2.7.11.22
Types de publication
Journal Article
Review
Langues
eng
Références
Breast Cancer Res Treat. 1998;52(1-3):1-15
pubmed: 10066068
Cell. 1999 Sep 17;98(6):859-69
pubmed: 10499802
Br J Cancer. 2000 Feb;82(3):675-82
pubmed: 10682682
J Cancer Res Clin Oncol. 2001 Sep;127(9):537-44
pubmed: 11570574
Oncogene. 2002 Aug 1;21(33):5031-7
pubmed: 12140753
Eur J Obstet Gynecol Reprod Biol. 2002 Nov 15;105(2):161-5
pubmed: 12381480
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23
pubmed: 12829800
J Med Chem. 2005 Apr 7;48(7):2388-406
pubmed: 15801831
Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S47-59
pubmed: 16113099
Br J Cancer. 2006 Mar 13;94(5):642-6
pubmed: 16495918
Br J Cancer. 2007 Jan 15;96(1):29-37
pubmed: 17179992
Curr Opin Oncol. 2007 Nov;19(6):573-8
pubmed: 17906454
J Clin Oncol. 2007 Nov 20;25(33):5158-64
pubmed: 17925543
Blood. 2009 Mar 19;113(12):2637-45
pubmed: 18981292
Ann Surg Oncol. 2009 Dec;16(12):3431-41
pubmed: 19834767
Breast Cancer Res. 2009;11(5):R77
pubmed: 19874578
Nat Cell Biol. 2009 Nov;11(11):1275-6
pubmed: 19884882
Lancet. 2010 Mar 6;375(9717):816-23
pubmed: 20206777
Haematologica. 2010 Jul;95(7):1098-105
pubmed: 20460644
Mol Cancer Ther. 2010 Aug;9(8):2344-53
pubmed: 20663931
Cell Cycle. 2010 Oct 15;9(20):4153-63
pubmed: 20948315
Cochrane Database Syst Rev. 2010 Dec 08;(12):CD007926
pubmed: 21154390
Endocr Relat Cancer. 2011 Apr 28;18(3):333-45
pubmed: 21367843
Cancer Discov. 2011 Sep;1(4):338-51
pubmed: 22049316
Clin Cancer Res. 2012 Jan 15;18(2):568-76
pubmed: 22090362
Gynecol Oncol. 2012 Oct;127(1):32-7
pubmed: 22735786
PLoS One. 2012;7(9):e46072
pubmed: 23029392
Gynecol Oncol. 2013 Jan;128(1):65-70
pubmed: 23085460
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2916-21
pubmed: 23359684
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Development. 2013 Aug;140(15):3079-93
pubmed: 23861057
Gynecol Oncol. 2013 Dec;131(3):613-8
pubmed: 24076063
Clin Chem. 2014 Jan;60(1):98-110
pubmed: 24170611
Tumour Biol. 2014 Jun;35(6):5395-9
pubmed: 24519066
Gynecol Oncol. 2014 May;133(2):370-4
pubmed: 24561031
Facts Views Vis Obgyn. 2013;5(3):179-86
pubmed: 24753943
Lancet Oncol. 2014 Jun;15(7):e268-78
pubmed: 24872110
Methods Mol Biol. 2014;1170:29-40
pubmed: 24906307
Cancer Cell. 2014 Jul 14;26(1):136-49
pubmed: 25002028
Genome Biol. 2014;15(6):122
pubmed: 25180339
Lancet Oncol. 2015 Jan;16(1):36-46
pubmed: 25467404
Clin Cancer Res. 2015 Mar 1;21(5):995-1001
pubmed: 25501126
J Natl Cancer Inst. 2014 Dec 12;107(1):402
pubmed: 25505230
Expert Opin Biol Ther. 2015 Feb;15(2):299-307
pubmed: 25539414
J Clin Oncol. 2015 Mar 10;33(8):930-6
pubmed: 25624430
Mod Pathol. 2015 Jun;28(6):836-44
pubmed: 25720322
World J Surg Oncol. 2015 Jun 25;13:208
pubmed: 26108802
J Clin Oncol. 2015 Nov 1;33(31):3535-40
pubmed: 26195695
Ann Oncol. 2016 Jan;27(1):16-41
pubmed: 26634381
Cell. 1989 Sep 22;58(6):1085-95
pubmed: 2673542
Clin Cancer Res. 2016 Jun 15;22(12):2865-73
pubmed: 26763250
Am Fam Physician. 2016 Mar 15;93(6):468-74
pubmed: 26977831
Cancer Res. 2016 Apr 15;76(8):2301-13
pubmed: 27020857
Nat Rev Clin Oncol. 2016 Jul;13(7):417-30
pubmed: 27030077
Sci Rep. 2016 May 10;6:25521
pubmed: 27160768
Cancer Discov. 2016 Jul;6(7):740-53
pubmed: 27217383
Cancer. 2016 Sep 15;122(18):2787-98
pubmed: 27308732
Br J Cancer. 2016 Jul 26;115(3):303-11
pubmed: 27351214
Cancer Treat Rev. 2016 Jul;48:61-8
pubmed: 27362548
Clin Cancer Res. 2016 Dec 1;22(23):5696-5705
pubmed: 27542767
N Engl J Med. 2016 Nov 17;375(20):1925-1936
pubmed: 27959613
Blood. 2017 Mar 30;129(13):1876-1878
pubmed: 28126927
J Pathol. 2017 Jun;242(2):152-164
pubmed: 28349562
PLoS One. 2017 May 4;12(5):e0177019
pubmed: 28472136
Clin Cancer Res. 2017 Sep 1;23(17):5218-5224
pubmed: 28533223
J Clin Oncol. 2017 Sep 1;35(25):2875-2884
pubmed: 28580882
Clin Cancer Res. 2017 Sep 15;23(18):5561-5572
pubmed: 28606920
Gynecol Oncol. 2017 Oct;147(1):158-166
pubmed: 28689667
Oncologist. 2017 Sep;22(9):1039-1048
pubmed: 28706010
J Clin Oncol. 2017 Nov 10;35(32):3638-3646
pubmed: 28968163
J Pathol Clin Res. 2017 Oct 14;3(4):279-293
pubmed: 29085668
Oncotarget. 2017 Aug 8;8(52):90532-90544
pubmed: 29163851
Cancer Res. 2018 Feb 1;78(3):742-757
pubmed: 29180466
Cancer Cell. 2017 Dec 11;32(6):761-776.e6
pubmed: 29232554
Breast Cancer Res Treat. 2018 Apr;168(2):287-297
pubmed: 29236235
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Lancet Oncol. 2018 Mar;19(3):295-309
pubmed: 29449189
Drug Des Devel Ther. 2018 Feb 16;12:321-330
pubmed: 29497278
Ann Oncol. 2018 Jul 1;29(7):1541-1547
pubmed: 29718092
Gynecol Oncol. 2018 Aug;150(2):274-281
pubmed: 29804638
Ann Oncol. 2018 Aug 1;29(8):1634-1657
pubmed: 30032243
Expert Opin Drug Metab Toxicol. 2018 Sep;14(9):891-900
pubmed: 30130984
Front Oncol. 2018 Aug 08;8:303
pubmed: 30135856
Cancer Discov. 2018 Nov;8(11):1390-1403
pubmed: 30206110
Clin Cancer Res. 2019 Jan 1;25(1):21-28
pubmed: 30224338
Biomed Pharmacother. 2018 Nov;107:1326-1341
pubmed: 30257348
Clin Cancer Res. 2019 Feb 1;25(3):921-927
pubmed: 30287548
Breast Cancer Res. 2018 Oct 19;20(1):123
pubmed: 30340505
Gynecol Oncol. 2019 Apr;153(1):175-183
pubmed: 30616900
Br J Cancer. 1988 Feb;57(2):205-12
pubmed: 3358913
Gynecol Oncol. 1983 Feb;15(1):10-7
pubmed: 6822361
Endocrinology. 1997 Mar;138(3):978-84
pubmed: 9048598